RxDoctor Payments DataLook up a doctor →

John Fenice, MD

Family Medicine · Wilmington, DENPI 1033138169

Payments from drug & device makers

$10,287in general payments, 2019–2025

Across 517 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$877
  • GSK$552
  • Otsuka America Pharmaceutical, Inc.$494
  • Lilly USA, LLC$473
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$10,09898%
  • Education$1902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,287 in reported general payments places this provider in the 90th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$110,304
Medicare patients
228
Services billed
1,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide30$36,905
JardianceEmpagliflozin30$36,193
OzempicSemaglutide27$31,910
FarxigaDapagliflozin Propanediol19$18,355
LinzessLinaclotide20$12,915
TradjentaLinagliptin11$8,139
MyrbetriqMirabegron11$7,442
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,987
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl50$5,947
Spiriva HandihalerTiotropium Bromide11$5,669
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,157
Omega-3 Acid Ethyl Esters15$1,849
Atorvastatin Calcium142$1,474
Levothyroxine Sodium131$1,438
Albuterol Sulfate HfaAlbuterol Sulfate39$1,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$18$44,33241 claims
Lilly USA, LLCMounjaro, Olanzapine$473$37,33644 claims
Novo NordiskOzempic$1,871$31,91027 claims
AstraZenecaFarxiga$877$18,35519 claims
AbbVieLinzess$2,366$12,91520 claims
Astellas Pharma US IncMyrbetriq$233$7,44211 claims
GSKTrelegy Ellipta$552$6,98711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 352 family medicine providers in Delaware.

Other family medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →